{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:51:02Z","timestamp":1792461062527,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Surg Endosc"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00464-026-12940-0","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T19:14:18Z","timestamp":1780946058000},"page":"6640-6648","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Differential impact of glucagon-like peptide-1 (GLP-1) receptor agonists for weight loss in the type 2 diabetic and non-diabetic populations"],"prefix":"10.1007","volume":"40","author":[{"given":"Iwanger-I.-Ter T.","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace C.","family":"Bloomfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike Y.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus H.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun C.","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo W.","family":"Hinojosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninh T.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan E.","family":"Azagury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0928-1799","authenticated-orcid":false,"given":"Nicholas J.","family":"Prindeze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"12940_CR1","unstructured":"Hales CM, Carroll MD, Fryar CD, Ogden CL (2020) Prevalence of obesity and severe obesity among adults: United States, 2017-2018. NCHS Data Brief No. 360, February 2020. https:\/\/www.cdc.gov\/nchs\/products\/databriefs\/db360.htm. Accessed 23 Nov 2025"},{"key":"12940_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1411892","volume":"373","author":"X Pi-Sunyer","year":"2015","unstructured":"Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, Lau DCW, le Roux CW, Violante Ortiz R, Jensen CB, Wilding JPH, SCALE Obesity and Prediabetes NN8022-1839 Study Group (2015) A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 373:11\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1411892","journal-title":"N Engl J Med"},{"key":"12940_CR3","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF, STEP 1 Study Group (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"12940_CR4","doi-asserted-by":"publisher","DOI":"10.1007\/s00464-025-12086-5","author":"I-I-TT Jia","year":"2025","unstructured":"Jia I-I-TT, Bloomfield GC, Chen MY, Cunningham MH, Azagury DE, Alimi YR, Prindeze NJ (2025) Analysis of the long-term impact of glucagon-like peptide-1 (GLP-1) receptor agonists for control of obesity and obesity-related comorbidities: a meta-analysis. Surg Endosc. https:\/\/doi.org\/10.1007\/s00464-025-12086-5","journal-title":"Surg Endosc"},{"key":"12940_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, Moher D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"12940_CR6","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4158\/EP.13.5.444","volume":"13","author":"P Viswanathan","year":"2007","unstructured":"Viswanathan P, Chaudhuri A, Bhatia R, Al-Atrash F, Mohanty P, Dandona P (2007) Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin. Endocr Pract 13:444\u2013450. https:\/\/doi.org\/10.4158\/EP.13.5.444","journal-title":"Endocr Pract"},{"key":"12940_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.clinthera.2007.01.015","volume":"29","author":"JB Buse","year":"2007","unstructured":"Buse JB, Klonoff DC, Nielsen LL, Guan X, Bowlus CL, Holcombe JH, Maggs DG, Wintle ME (2007) Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. Clin Ther 29:139\u2013153. https:\/\/doi.org\/10.1016\/j.clinthera.2007.01.015","journal-title":"Clin Ther"},{"key":"12940_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.4158\/EP11169.OR","volume":"18","author":"A Varanasi","year":"2012","unstructured":"Varanasi A, Patel P, Makdissi A, Dhindsa S, Chaudhuri A, Dandona P (2012) Clinical use of liraglutide in type 2 diabetes and its effects on cardiovascular risk factors. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 18:140\u2013145. https:\/\/doi.org\/10.4158\/EP11169.OR","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"12940_CR9","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/j.1463-1326.2011.01393.x","volume":"13","author":"KY Thong","year":"2011","unstructured":"Thong KY, Jose B, Sukumar N, Cull ML, Mills AP, Sathyapalan T, Shafiq W, Rigby AS, Walton C, Ryder REJ, ABCD Nationwide Exenatide Audit Contributors (2011) Safety, efficacy and tolerability of exenatide in combination with insulin in the association of British clinical diabetologists nationwide exenatide audit*. Diabetes Obes Metab 13:703\u2013710. https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01393.x","journal-title":"Diabetes Obes Metab"},{"key":"12940_CR10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/dme.12137","volume":"30","author":"GC Hall","year":"2013","unstructured":"Hall GC, McMahon AD, Dain M-P, Wang E, Home PD (2013) Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK. Diabet Med J Br Diabet Assoc 30:681\u2013686. https:\/\/doi.org\/10.1111\/dme.12137","journal-title":"Diabet Med J Br Diabet Assoc"},{"key":"12940_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050117","volume":"7","author":"DJ Cuthbertson","year":"2012","unstructured":"Cuthbertson DJ, Irwin A, Gardner CJ, Daousi C, Purewal T, Furlong N, Goenka N, Thomas EL, Adams VL, Pushpakom SP, Pirmohamed M, Kemp GJ (2012) Improved glycaemia correlates with liver fat reduction in obese, type 2 diabetes, patients given glucagon-like peptide-1 (GLP-1) receptor agonists. PLoS ONE 7:e50117. https:\/\/doi.org\/10.1371\/journal.pone.0050117","journal-title":"PLoS ONE"},{"key":"12940_CR12","first-page":"2677","volume":"125","author":"G-H Yuan","year":"2012","unstructured":"Yuan G-H, Song W-L, Huang Y-Y, Guo X-H, Gao Y (2012) Efficacy and tolerability of exenatide monotherapy in obese patients with newly diagnosed type 2 diabetes: a randomized, 26 weeks metformin-controlled, parallel-group study. Chin Med J (Engl) 125:2677\u20132681","journal-title":"Chin Med J (Engl)"},{"key":"12940_CR13","first-page":"523","volume":"72","author":"EFS van Velsen","year":"2014","unstructured":"van Velsen EFS, Lamers J, Blok V, van Leendert RJM, Kiewiet-Kemper RM (2014) A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice. Neth J Med 72:523\u2013527","journal-title":"Neth J Med"},{"issue":"5","key":"12940_CR14","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/ijo.2013.149","volume":"38","author":"MEJ Lean","year":"2014","unstructured":"Lean MEJ, Carraro R, Finer N, Hartvig H, Lindegaard ML, R\u00f6ssner S, Van Gaal L, Astrup A, NN8022-1807 Investigators (2014) Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults. Int J Obes 38(5):689\u2013697. https:\/\/doi.org\/10.1038\/ijo.2013.149","journal-title":"Int J Obes"},{"key":"12940_CR15","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.2337\/dc13-2761","volume":"37","author":"M Nauck","year":"2014","unstructured":"Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z (2014) Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care 37:2149\u20132158. https:\/\/doi.org\/10.2337\/dc13-2761","journal-title":"Diabetes Care"},{"key":"12940_CR16","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1001\/jama.2015.9676","volume":"314","author":"MJ Davies","year":"2015","unstructured":"Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skj\u00f8th TV, Andreasen AH, Jensen CB, DeFronzo RA, NN8022-1922 Study Group (2015) Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE Diabetes randomized clinical trial. JAMA 314:687\u2013699. https:\/\/doi.org\/10.1001\/jama.2015.9676","journal-title":"JAMA"},{"key":"12940_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1007\/s11096-015-0219-8","volume":"38","author":"SA de Boer","year":"2016","unstructured":"de Boer SA, Lefrandt JD, Petersen JF, Boersma HH, Mulder DJ, Hoogenberg K (2016) The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour. Int J Clin Pharm 38:144\u2013151. https:\/\/doi.org\/10.1007\/s11096-015-0219-8","journal-title":"Int J Clin Pharm"},{"key":"12940_CR18","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1038\/ijo.2016.52","volume":"40","author":"A Blackman","year":"2016","unstructured":"Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, Claudius B, Jensen CB, Mignot E (2016) Effect of liraglutide 3.0\u2009mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes 40:1310\u20131319. https:\/\/doi.org\/10.1038\/ijo.2016.52","journal-title":"Int J Obes"},{"key":"12940_CR19","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1001\/jama.2016.1252","volume":"315","author":"I Lingvay","year":"2016","unstructured":"Lingvay I, P\u00e9rez Manghi F, Garc\u00eda-Hern\u00e1ndez P, Norwood P, Lehmann L, Tarp-Johansen MJ, Buse JB, DUAL V Investigators (2016) Effect of insulin glargine up-titration vs insulin degludec\/liraglutide on glycated hemoglobin levels in patients with uncontrolled type 2 diabetes: the DUAL V randomized clinical trial. JAMA 315:898\u2013907. https:\/\/doi.org\/10.1001\/jama.2016.1252","journal-title":"JAMA"},{"key":"12940_CR20","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.jdiacomp.2016.01.013","volume":"30","author":"H Quan","year":"2016","unstructured":"Quan H, Zhang H, Wei W, Fang T (2016) Gender-related different effects of a combined therapy of exenatide and metformin on overweight or obesity patients with type 2 diabetes mellitus. J Diabetes Complications 30:686\u2013692. https:\/\/doi.org\/10.1016\/j.jdiacomp.2016.01.013","journal-title":"J Diabetes Complications"},{"key":"12940_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Zinman B, Bergenstal RM, Buse JB, LEADER Steering Committee, LEADER Trial Investigators (2016) Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375:311\u2013322. https:\/\/doi.org\/10.1056\/NEJMoa1603827","journal-title":"N Engl J Med"},{"key":"12940_CR22","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, Lingvay I, Rosenstock J, Seufert J, Warren ML, Woo V, Hansen O, Holst AG, Pettersson J, Vilsb\u00f8ll T, SUSTAIN-6 Investigators (2016) Semaglutide and cardiovascular outcomes in patients with type 2 Diabetes. N Engl J Med 375:1834\u20131844. https:\/\/doi.org\/10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"12940_CR23","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1111\/dom.13266","volume":"20","author":"C Guja","year":"2018","unstructured":"Guja C, Fr\u00edas JP, Somogyi A, Jabbour S, Wang H, Hardy E, Rosenstock J (2018) Effect of exenatide QW or placebo, both added to titrated insulin glargine, in uncontrolled type 2 diabetes: the DURATION-7 randomized study. Diabetes Obes Metab 20:1602\u20131614. https:\/\/doi.org\/10.1111\/dom.13266","journal-title":"Diabetes Obes Metab"},{"key":"12940_CR24","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","volume":"389","author":"CW le Roux","year":"2017","unstructured":"le Roux CW, Astrup A, Fujioka K, Greenway F, Lau DCW, Van Gaal L, Ortiz RV, Wilding JPH, Skj\u00f8th TV, Manning LS, Pi-Sunyer X, SCALE Obesity Prediabetes NN8022-1839 Study Group (2017) 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet Lond Engl. 389:1399\u20131409","journal-title":"Lancet Lond Engl."},{"key":"12940_CR25","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/dom.13107","volume":"20","author":"S Unni","year":"2018","unstructured":"Unni S, Wittbrodt E, Ma J, Schauerhamer M, Hurd J, Ruiz-Negr\u00f3n N, McAdam-Marx C (2018) Comparative effectiveness of once-weekly glucagon-like peptide-1 receptor agonists with regard to 6-month glycaemic control and weight outcomes in patients with type 2 diabetes. Diabetes Obes Metab 20:468\u2013473. https:\/\/doi.org\/10.1111\/dom.13107","journal-title":"Diabetes Obes Metab"},{"key":"12940_CR26","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1111\/dom.13335","volume":"20","author":"JA Overbeek","year":"2018","unstructured":"Overbeek JA, Heintjes EM, Huisman EL, Tikkanen CK, van Diermen AW, Penning-van Beest FJA, Herings RMC (2018) Clinical effectiveness of liraglutide vs basal insulin in a real-world setting: evidence of improved glycaemic and weight control in obese people with type 2 diabetes. Diabetes Obes Metab 20:2093\u20132102. https:\/\/doi.org\/10.1111\/dom.13335","journal-title":"Diabetes Obes Metab"},{"key":"12940_CR27","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","volume":"392","author":"PM O\u2019Neil","year":"2018","unstructured":"O\u2019Neil PM, Birkenfeld AL, McGowan B, Mosenzon O, Pedersen SD, Wharton S, Carson CG, Jepsen CH, Kabisch M, Wilding JPH (2018) Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 392:637\u2013649. https:\/\/doi.org\/10.1016\/S0140-6736(18)31773-2","journal-title":"Lancet"},{"key":"12940_CR28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.dsx.2018.09.007","volume":"13","author":"A Hemmer","year":"2019","unstructured":"Hemmer A, Maiter D, Buysschaert M, Preumont V (2019) Long-term effects of GLP-1 receptor agonists in type 2 diabetic patients: a retrospective real-life study in 131 patients. Diabetes Metab Syndr 13:332\u2013336. https:\/\/doi.org\/10.1016\/j.dsx.2018.09.007","journal-title":"Diabetes Metab Syndr"},{"key":"12940_CR29","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, Probstfield J, Riesmeyer JS, Riddle MC, Ryd\u00e9n L, Xavier D, Atisso CM, Dyal L, Hall S, Rao-Melacini P, Wong G, Avezum A, Basile J, Chung N, Conget I, Cushman WC, Franek E, Hancu N, Hanefeld M, Holt S, Jansky P, Keltai M, Lanas F, Leiter LA, Lopez-Jaramillo P, Cardona Munoz EG, Pirags V, Pogosova N, Raubenheimer PJ, Shaw JE, Sheu WH-H, Temelkova-Kurktschiev T, Investigators REWIND (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet Lond Engl 394:121\u2013130. https:\/\/doi.org\/10.1016\/S0140-6736(19)31149-3","journal-title":"Lancet Lond Engl"},{"key":"12940_CR30","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, Jeppesen OK, Lingvay I, Mosenzon O, Pedersen SD, Tack CJ, Thomsen M, Vilsb\u00f8ll T, Warren ML, Bain SC, PIONEER 6 Investigators (2019) Oral semaglutide and cardiovascular outcomes in patients with Type 2 diabetes. N Engl J Med 381:841\u2013851. https:\/\/doi.org\/10.1056\/NEJMoa1901118","journal-title":"N Engl J Med"},{"key":"12940_CR31","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.2337\/dc19-1745","volume":"43","author":"WT Garvey","year":"2020","unstructured":"Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A, Skovgaard D, Sugimoto D, Jensen C, Mosenzon O (2020) Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care 43:1085\u20131093. https:\/\/doi.org\/10.2337\/dc19-1745","journal-title":"Diabetes Care"},{"key":"12940_CR32","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.pcd.2019.05.006","volume":"14","author":"J Moreno-Fernandez","year":"2020","unstructured":"Moreno-Fernandez J, Garcia-Seco JA, Seco Segura AM, Garcia-Seco F, Rozas Moreno PJ, Aguirre Sanchez-Covisa M (2020) Liraglutide vs. lixisenatide in obese type 2 diabetes mellitus patients: What effect should we expect in routine clinical practice? Prim Care Diabetes 14:68\u201374. https:\/\/doi.org\/10.1016\/j.pcd.2019.05.006","journal-title":"Prim Care Diabetes"},{"key":"12940_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2020.107548","volume":"34","author":"KE Elkind-Hirsch","year":"2020","unstructured":"Elkind-Hirsch KE, Shaler D, Harris R (2020) Postpartum treatment with liraglutide in combination with metformin versus metformin monotherapy to improve metabolic status and reduce body weight in overweight\/obese women with recent gestational diabetes: a double-blind, randomized, placebo-controlled study. J Diabetes Complications 34:107548. https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107548","journal-title":"J Diabetes Complications"},{"key":"12940_CR34","doi-asserted-by":"publisher","unstructured":"Davies M, F\u00e6rch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I, STEP 2 Study Group (2021) Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet Lond Engl 397:971\u2013984. https:\/\/doi.org\/10.1016\/S0140-6736(21)00213-","DOI":"10.1016\/S0140-6736(21)00213"},{"key":"12940_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.742873","volume":"12","author":"M Rodgers","year":"2021","unstructured":"Rodgers M, Migdal AL, Rodr\u00edguez TG, Chen Z-Z, Nath AK, Gerszten RE, Kasid N, Toschi E, Tripaldi J, Heineman B, Phan M, Ngo L, Maratos-Flier E, Dushay J (2021) Weight loss outcomes among early high responders to exenatide treatment: a randomized, placebo controlled study in overweight and obese women. Front Endocrinol 12:742873. https:\/\/doi.org\/10.3389\/fendo.2021.742873","journal-title":"Front Endocrinol"},{"key":"12940_CR36","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-673(21)01751-7","volume":"398","author":"DCW Lau","year":"2021","unstructured":"Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietil\u00e4inen KH, Rubino D, Batterham RL (2021) Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet Lond Engl 398:2160\u20132172. https:\/\/doi.org\/10.1016\/S0140-673(21)01751-7","journal-title":"Lancet Lond Engl"},{"key":"12940_CR37","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","volume":"397","author":"LB Enebo","year":"2021","unstructured":"Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW (2021) Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2\u00b74 mg for weight management: a randomised, controlled, phase 1b trial. Lancet Lond Engl 397:1736\u20131748. https:\/\/doi.org\/10.1016\/S0140-6736(21)00845-X","journal-title":"Lancet Lond Engl"},{"key":"12940_CR38","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1001\/jama.2021.3224","volume":"325","author":"D Rubino","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, Hesse D, Greenway FL, Jensen C, Lingvay I, Mosenzon O, Rosenstock J, Rubio MA, Rudofsky G, Tadayon S, Wadden TA, Dicker D, STEP 4 Investigators (2021) Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA 325:1414\u20131425. https:\/\/doi.org\/10.1001\/jama.2021.3224","journal-title":"JAMA"},{"key":"12940_CR39","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1001\/jama.2021.1831","volume":"325","author":"TA Wadden","year":"2021","unstructured":"Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, Lingvay I, O\u2019Neil PM, Rubino DM, Skovgaard D, Wallenstein SOR, Garvey WT, STEP 3 Investigators (2021) Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA 325:1403\u20131413. https:\/\/doi.org\/10.1001\/jama.2021.1831","journal-title":"JAMA"},{"key":"12940_CR40","doi-asserted-by":"publisher","first-page":"3019","DOI":"10.1210\/clinem\/dgab408","volume":"106","author":"KE Elkind-Hirsch","year":"2021","unstructured":"Elkind-Hirsch KE, Chappell N, Seidemann E, Storment J, Bellanger D (2021) Exenatide, dapagliflozin, or phentermine\/topiramate differentially affect metabolic profiles in polycystic ovary syndrome. J Clin Endocrinol Metab 106:3019\u20133033. https:\/\/doi.org\/10.1210\/clinem\/dgab408","journal-title":"J Clin Endocrinol Metab"},{"key":"12940_CR41","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1159\/000518325","volume":"14","author":"CL Haase","year":"2021","unstructured":"Haase CL, Serratore Achenbach MG, Lucrezi G, Jeswani N, Maurer S, Egermann U (2021) Use of liraglutide 3.0 mg for weight management in a real-world setting in Switzerland. Obes Facts 14:568\u2013576. https:\/\/doi.org\/10.1159\/000518325","journal-title":"Obes Facts"},{"key":"12940_CR42","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.soard.2022.02.008","volume":"18","author":"T Wu","year":"2022","unstructured":"Wu T, Wong CKH, Tang EHM, Man KKC, Wong SKH, Au ICH, Tse ETY, Chan EWY, Grieve E, Wu O, Ng EKW, Wong ICK (2022) The comparative effects of metabolic surgery, SGLT2i, or GLP-1RA in patients with obesity and type 2 diabetes: a retrospective cohort study. Surg Obes Relat Dis Off J Am Soc Bariatr Surg 18:762\u2013771. https:\/\/doi.org\/10.1016\/j.soard.2022.02.008","journal-title":"Surg Obes Relat Dis Off J Am Soc Bariatr Surg"},{"key":"12940_CR43","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U, O\u2019Neil PM, Rosenstock J, S\u00f8rrig R, Wadden TA, Wizert A, Garvey WT, STEP 8 Investigators (2022) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA 327:138\u2013150. https:\/\/doi.org\/10.1001\/jama.2021.23619","journal-title":"JAMA"},{"key":"12940_CR44","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","volume":"28","author":"WT Garvey","year":"2022","unstructured":"Garvey WT, Batterham RL, Bhatta M, Buscemi S, Christensen LN, Frias JP, J\u00f3dar E, Kandler K, Rigas G, Wadden TA, Wharton S, STEP 5 Study Group (2022) Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med 28:2083\u20132091. https:\/\/doi.org\/10.1038\/s41591-022-02026-4","journal-title":"Nat Med"},{"key":"12940_CR45","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1111\/cen.14901","volume":"99","author":"SA Tee","year":"2023","unstructured":"Tee SA, Tsatlidis V, Razvi S (2023) The GLP-1 receptor agonist exenatide reduces serum TSH by its effect on body weight in people with type 2 diabetes. Clin Endocrinol (Oxf) 99:401\u2013408. https:\/\/doi.org\/10.1111\/cen.14901","journal-title":"Clin Endocrinol (Oxf)"},{"key":"12940_CR46","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1111\/dom.15141","volume":"25","author":"K Stefanakis","year":"2023","unstructured":"Stefanakis K, Kokkinos A, Argyrakopoulou G, Konstantinidou SK, Simati S, Kouvari M, Kumar A, Kalra B, Kumar M, Bontozoglou N, Kyriakopoulou K, Mantzoros CS (2023) Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone\/bupropion and can predict future weight loss and metabolic improvements: a 6-month long interventional study. Diabetes Obes Metab 25:2561\u20132574. https:\/\/doi.org\/10.1111\/dom.15141","journal-title":"Diabetes Obes Metab"},{"key":"12940_CR47","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1002\/oby.23596","volume":"31","author":"S Santini","year":"2023","unstructured":"Santini S, Vionnet N, Pasquier J, Gonzalez-Rodriguez E, Fraga M, Pitteloud N, Favre L (2023) Marked weight loss on liraglutide 3.0 mg: real-life experience of a Swiss cohort with obesity. Obes Silver Spring Md 31:74\u201382. https:\/\/doi.org\/10.1002\/oby.23596","journal-title":"Obes Silver Spring Md"},{"key":"12940_CR48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"V Perkovic","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, Baeres FMM, Idorn T, Bosch-Traberg H, Lausvig NL, Pratley R, FLOW Trial Committees and Investigators (2024) Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 391:109\u2013121. https:\/\/doi.org\/10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"}],"container-title":["Surgical Endoscopy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-026-12940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00464-026-12940-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00464-026-12940-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T21:11:12Z","timestamp":1786396272000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00464-026-12940-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":48,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["12940"],"URL":"https:\/\/doi.org\/10.1007\/s00464-026-12940-0","relation":{},"ISSN":["0930-2794","1432-2218"],"issn-type":[{"value":"0930-2794","type":"print"},{"value":"1432-2218","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"assertion":[{"value":"9 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors including Ms. Iwanger-T-Ter Jia, Ms. Grace Bloomfield, Mr. Mike Chen, Mr. Marcus Cunningham, Dr. Annie Wang, Dr. Shaun Daly, Dr. Marcelo Hinojosa, Dr. Brian Smith, Dr. Ninh Nguyen, Dr. Dan Azagury, and Dr. Nicholas Prindeze have no conflict of interest or financial ties to disclose.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}]}}